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The lack of predictive in vitromodels for behavioral phenotypes impedes rapid advancement
in neuropharmacology and psychopharmacology. In vivo behavioral assays are more pre-
dictive of activity in human disorders, but such assays are often highly resource-intensive.
Here we describe the successful application of a computer vision-enabled system to iden-
tify potential neuropharmacological activity of two new mechanisms.The analytical system
was trained using multiple drugs that are used clinically to treat depression, schizophrenia,
anxiety, and other psychiatric or behavioral disorders. During blinded testing the PDE10
inhibitor TP-10 produced a signature of activity suggesting potential antipsychotic activity.
This ﬁnding is consistent withTP-10’s activity inmultiple rodentmodels that is similar to that
of clinically used antipsychotic drugs. The CK1ε inhibitor PF-670462 produced a signature
consistent with anxiolytic activity and, at the highest dose tested, behavioral effects similar
to that of opiate analgesics. Neither TP-10 nor PF-670462 was included in the training set.
Thus, computer vision-based behavioral analysis can facilitate drug discovery by identifying
neuropharmacological effects of compounds acting through new mechanisms.
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INTRODUCTION
Pharmaceutical companies and many academic centers have thou-
sands of high-quality compounds that represent potential new
drugs. These high-quality compound collections contain thor-
oughly studied development candidates and, in many cases, “old”
drugs that were generated for non-CNS disorders but that might
be useful therapies for one or more psychiatric diseases. How-
ever, testing these compounds for activity relevant to treating
psychiatric diseases is challenging. Whereas some disease areas,
such as cancer or infectious disease, are relatively amenable to
high-throughput in vitro testing of hundreds of thousands of
compounds, psychiatric diseases are not. Because psychiatric dis-
eases generally result from disorders of cell–cell communica-
tion or circuitry, intact systems are required to detect improve-
ment in disease-relevant endpoints. These endpoints are typically
behavioral in nature, often requiring human observation and
interpretation.
Resource-intensive behavioral experiments are expensive, slow,
and frequently subjective. The need for observers to be blinded
to the treatment group of each animal increases the resources
required to appropriately dose and randomize animals in a way
that is invisible to the observer. Furthermore, multiple comple-
mentary behavioral assays are required to determine whether
observed effects are robust and are not due to undesired effects,
such as sedation (Crawley and Paylor, 1997).
Thus, the discovery of new neuropharmacological drugs with
novel mechanisms of action is impeded by the absence of
high-throughput, robust, and objective behavioral assays. Very
recently a 96-well behavioral assay measuring the photomotor
response of zebraﬁsh embryos demonstrated that different classes
of neuropharmacological compounds cause distinct patterns of
responses (Kokel et al., 2010). Such an assay is relatively inexpen-
sive and is well suited to screening high numbers of compounds
about which little is known.
For high-quality compounds, particularly compounds that
have entered human testing, a rodent system offers advantages.
Rodent behaviors in response to existing neuropharmacologi-
cal agents are very well characterized. For advanced compounds,
rodent pharmacokinetics and safety are often known, and sufﬁ-
cient quantities of these compounds generally exist to support
rodent studies.
To enable testing of many compounds for behavioral
effects relevant to psychiatric disease, PsychoGenics developed
SmartCube™, an automated system in which behaviors of
compound-treatedmice are capturedbydigital video and analyzed
with computer algorithms (Brunner et al., 2002). PGI Analytical
Systems uses data from SmartCube™to compare the behavioral
signature of a test compound to a database of behavioral signa-
tures obtained using a large set of diverse reference compounds.
In this way, the neuropharmacological effects of a test compound
can be predicted by similarity to major classes of compounds, such
as antipsychotics, anxiolytics, and antidepressants. This approach
is ideally suited to screening collections of existing drugs or drug
candidates for previously unknown neuropharmacology, which
could expedite the development of new and unexpected treat-
ments for psychiatric disorders. In this paper, we demonstrate
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that this system can detect relevant CNS activity of compounds
representing mechanisms beyond those used clinically to treat
psychiatric disorders.
MATERIALS AND METHODS
An overview of PGI Analytical Systems, a rapid, computer vision-
enabled murine screening system for neuropharmacological activ-
ity, is shown in Figure 1. The PGI Analytical Systems training
set consisted of hundreds of doses of clinically approved ref-
erence drugs, grouped per indication (e.g., anxiolytics, antide-
pressants, etc.). Drugs were injected 15 min before the test, and
multiple challenges were presented over the course of the test
session. At least 12 mice were used in each treatment group. Dig-
ital videos of the subjects were processed with computer vision
algorithms to extract over 2,000 dependent measures including
frequency and duration of behavioral states such as grooming,
rearing, etc., and many other features obtained during the test
session.
A proprietary machine learning algorithm was developed to
train a probabilistic classiﬁer that mapped the extracted computer
vision feature values from the training set to their corresponding
CNS indications. This tool was used to establish a reference data-
base of therapeutic class signatures and provided a mechanism
to determine the CNS probabilistic proﬁle of an arbitrary test
sample.
Our reference database comprises 14 classes of drugs with some
of the major classes, such as the antidepressant class, comprising
several subclasses with representatives of most of the drugs in the
market. The best performing classiﬁers during“test set”assessment
were chosen from our evaluation tests and two separate types of
classiﬁers were built that make independent predictions: one at the
therapeutic class level and one at the level of highly performing
subclasses. The behavioral signatures of the test drugs were scored
by these classiﬁers to predict potential therapeutic utility.
To evaluate the ability of the PGI Analytical System to detect
relevant behavioral responses to novel compounds, we tested two
compounds that represent mechanisms not yet used clinically to
treat psychiatric disorders but that impact relevant behavioral end-
points in rodents. The two test compounds, TP-10 and PF-670462,
had not been included in the computer algorithm training set.
TP-10 is a sub-nanomolar inhibitor of PDE10A, a dual-substrate
phosphodiesterase expressed in medium spiny neurons of the
striatum that regulates striatal output by regulating both cAMP
and cGMP hydrolysis (Strick et al., 2007). TP-10 demonstrates
multiple behavioral effects in rodents that are consistent with
clinically effective antipsychotics, including decreased locomo-
tor activity, inhibition of conditioned avoidance response, and
improvement of amphetamine-induced deﬁcits in auditory gat-
ing (Schmidt et al., 2008). PF-670462 is a casein kinase Iε (CK1ε)
inhibitor (Badura et al., 2007).
All compounds were dissolved in a pharmasolve, PEG, PG
mixture, and were injected i.p. 15 min before the behavioral test.
In a follow-up experiment PF-670462 was administered s.c. 13 h
before the behavioral test because of its known effects on circadian
rhythm at 50 mg/kg s.c. (Badura et al., 2007); this procedure was
done both in the morning and evening.
As a follow-up test to conﬁrm the anxiolytic signature of PF-
670462 we use the marble burying test. PF-670462 was dissolved
in 40% cyclodextrin and injected at 10 and 30 mg/kg, s.c. 15 min
before the 30-min test. We measured number of marbles buried
and distance traveled.
Experimenters were blind to the mechanisms of action of both
compounds and to the dose being used. The Institutional Animal
Care and Use Committee of PsychoGenics reviewed and approved
the animal use in these studies. The animal care and use pro-
gram is fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, International.
RESULTS
In the PGI Analytical System, TP-10 produced a dose-dependent
signature of activity most similar to that of known antipsychotics,
particularly at the 1-mg/kgdose (Figure 2). TP-10 exhibited a steep
dose–response curve in this system, consistent with its steep dose–
response curve in other rodent models (Schmidt et al., 2008). At
the lower 0.5 mg/kg dose, TP-10’s activity is more similar to that
of the vehicle than to any class of drugs in the reference data-
base. At the higher dose of 2 mg/kg, TP-10 produced a behavioral
pattern that is quite different from that of the vehicle yet not spe-
ciﬁc to any one class. Notably, TP-10 activity at the 2-mg/kg dose
has a large behavioral component similar to that of high-dose
FIGURE 1 | PGI Analytical Systems combine proprietary hardware, robotics, computer vision, and data mining techniques to collect thousands of
behavioral features in a single test session and extract unique signatures for each compound.These signatures are compared with the signatures
obtained from reference compounds (shown to have clinical efﬁcacy) in different therapeutic classes and subclasses to predict clinical utility.
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FIGURE 2 |The PDE10A inhibitorTP-10 produced a signature of activity
suggesting potential antipsychotic activity.The size of a given colored
region on each bar indicates the probability that the activity of TP-10 at that
dose matches a given class of neuropharmacological agents. The size of the
white area represents that probability that the activity is more similar to
that of the vehicle rather than to that of any compounds in the reference
database. The drug was injected i.p., 15min before testing.
FIGURE 3 | Drug signatures of four of the antipsychotic drugs included
in the reference dataset: aripiprazole, clozapine, haloperidol, and
olanzapine. Numbers below each bar represent doses in mg/kg
administered i.p. 15min before testing.
FIGURE 4 |The CK1ε inhibitor PF-670462 demonstrated a signature
consistent with anxiolytic activity (yellow) and, at the highest dose
tested, behavioral effects similar to that of opiate analgesics (pink),
although this dose is higher that doses tested previously in rodents
and may reflect non-specific effects.The drug was injected i.p. 15min
before the test in studies represented by the ﬁve left-most bars of the
chart. To assess potentially delayed behavioral effects due to its effects on
circadian rhythm, PF-670462 was injected s.c. 13 h before testing in the
morning (AM) or in the afternoon (PM). This procedure revealed no delayed
effects.
antidepressants but not medium-dose antidepressants. Interest-
ingly, three of the four reference antipsychotic signatures shown
in Figure 3 also have a larger high-dose antidepressant-like com-
ponent at their highest doses. Overall, the proﬁle of TP-10 in this
computer-aided screening system is similar to that of clinically
used antipsychotic drugs (Gleason and Shannon, 1997; Powell
et al., 2008; Ishii et al., 2010). This observation is consistent
with TP-10’s activity in multiple rodent models (Schmidt et al.,
2008), suggesting that the PGI Analytical Systems can identify
antipsychotic-like activity of compounds acting through novel
mechanisms.
In contrast to PDE10A, for which considerable literature data
support its role as an antipsychotic target, the potential useful-
ness of altering CK1ε’s effects on circadian rhythm for treating
psychiatric disorders is unknown. CK1ε is an important regula-
tor of period proteins (PER) that regulate the clock mechanism
in cells (Lee et al., 2001). Clearly, improved regulation of circa-
dian rhythm could improve functioning in patients with sleep
disorders. Furthermore, disruptions of the sleep–wake cycle can
affect cognition, memory, and mood (Benca et al., 2009). CK1ε is
also involved in DARP32 phosphorylation and thus participates in
dopamine-dependent behavioral activation (Bryant et al., 2009).
Thus, the CK1ε mechanism is a good candidate for screening in a
system that may identify behavioral signatures relevant to a wide
variety of psychiatric disorders.
In the PGI Analytical System at intermediate doses of 30 and
50 mg/kg, the CK1ε inhibitor PF-670462 (Badura et al., 2007)
demonstrated a signature consistent with anxiolytic, but not seda-
tive/hypnotic, activity (Figure 4). Because PF-670462 produces
changes in circadian rhythm (Badura et al., 2007), we tested
whether administering PF-670462 to mice 13 h prior to testing
might produce a more relevant behavioral signature. Interestingly,
the compound had almost no detectable behavioral effects in this
system when dosed 13 h before testing, either in the morning (5:30
am) or the afternoon (7 pm). The anxiolytic signature of PF-
670462 seen at the 30, but not 10, mg/kg dose was conﬁrmed
in the marble burying test, in which the higher dose decreased
marbles buried without a decrease in locomotion (Figure 5).
DISCUSSION
Our work demonstrates the usefulness of a computer vision-based
system for identifying behavioral effects of novel compounds and
mechanisms in a relatively high-throughput in vivo assay. As one
example, the PDE10A inhibitor TP-10 demonstrated a behavioral
signature in thePGIAnalytical System thatwasmore similar to that
of known antipsychotics than to that of other classes of neurophar-
macological agents. Although the efﬁcacy of PDE10A inhibition
in humans has not been tested, the activity of TP-10 here is con-
sistent with effects of clinically used antipsychotics in multiple rat
in vivo assays (Schmidt et al., 2008). Importantly, the steep dose–
response curve of TP-10 was also consistent between the computer
vision-based system and traditional rodent assays. Interestingly,
TP-10 was ineffective in two mouse pre-pulse inhibition models
(Schmidt et al., 2008), although it showed an antipsychotic-like
signature in mice in the present study. The computer vision-based
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FIGURE 5 |The CK1ε inhibitor PF-670462 shows anxiolytic activity in
the marble burying test with a strong yet non-significant trend at
10mg/kg and a significant effect at 30mg/kg, consistent with the
dose–response anxiolytic signature uncovered by the high-throughput
screen [ANOVA F (4,43)>8.8, p<0.0001; Fisher PLSD p<0.02].The
drug was injected s.c. 15min before the 30-min test. There were no
signiﬁcant effects on locomotion.
system, which measures hundreds of small behavioral events, may
reveal more relationships because of its ability to assess compound
effects more broadly than a model designed to test one speciﬁc
functional hypothesis.
The TP-10 behavioral signature at the highest dose tested sug-
gested a small degree of activity similar to that of high-dose
antidepressants. This feature was observed with the higher doses
of most of the four reference antipsychotics in Figure 3, as well,
suggesting that the similarity is due to side effects caused by high
doses of all such compounds.
The computer vision-based system also suggested new
hypotheses regarding the behavioral effects of CK1ε inhibition.
Other than modulation of circadian rhythm (Badura et al., 2007),
behavioral effects of PF-670462 are unknown. We found that
moderate doses of PF-670462 produced activity similar to that
of anxiolytic agents, but not sedative/hypnotics. We followed up
this result in the marble burying test, an assay predictive of anxi-
olytic therapeutic potential, and conﬁrmed that a dose of 30 mg/kg
has anxiolytic activity (Figure 5).
In summary, our data demonstrate that the PGI Analytics
computer vision-based system rapidly detects relevant behavioral
effects of compounds acting through new mechanisms. Because
the assay and data analysis are highly automated, use of the system
eliminates the need for subjective human observation and evalu-
ation of behavior, thus eliminating signiﬁcant resource require-
ments along with much of the potential for bias inherent in
subjectivemeasurements. This approach is ideally suited to screen-
ing libraries of existing drugs or drug candidates for previously
unknown neuropharmacology, which could expedite the develop-
ment of new and unexpected treatments for psychiatric disorders.
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